Boardroom Alpha
Start trial
Boardroom Alpha
BEAM · Additional Proxy Materials (DEFA14A) · Filed April 17, 2026

Beam Therapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 17, 2026
Ticker
BEAM
Accession
0001193125-26-161541
Beam Therapeutics Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

Consult the filing for more details.

About Beam Therapeutics Inc
Market cap
$3.0B
1Y TSR
+76.6%
3Y TSR
−3.0%
Board grade
C-
Sector
Healthcare
CEO
John M Evans
Last annual meeting: Jun 3, 2026 · View full Beam Therapeutics Inc profile →
DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

 

 

☐

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐

Definitive Proxy Statement

☒

Definitive Additional Materials

☐

Soliciting Material under §240.14a-12

BEAM THERAPEUTICS INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than Registrant)

Payment of Filing Fee (Check the appropriate box):

 

 

 

 

 

☒

No fee required.

☐

Fee paid previously with preliminary materials.

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


 

img243671807_0.jpg

 

img243671807_1.jpg

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting ForecastSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Beam Therapeutics Inc (BEAM)

Continue researching
Reference

Frequently asked questions

When did Beam Therapeutics Inc file this DEFA14A?
Beam Therapeutics Inc (BEAM) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 17, 2026. The accession number assigned by EDGAR is 0001193125-26-161541.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Consult the filing for more details. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Beam Therapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Beam Therapeutics Inc has filed under CIK 1745999, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer